RY10-4 suppressed metastasis of MDA-MB-231 by stabilizing ECM and E-cadherin

Biomedicine and Pharmacotherapy

Volumn 68, Issue 4, 2014, Pages 439-445

  Liu, Ziwei ^a   Liu, Zhimei ^b   Zhang, Xiulan ^a   Xue, Pingping ^c   Zhang, Heng ^a  

^a WUHAN INSTITUTE OF TECHNOLOGY   (China)

^b Humanwell Healthcare (Group) Co Ltd   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

E cadherin; MAPK; Metastasis; MMP 2 9; RY10 4; catenin

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ACTIN; BETA CATENIN; FIBRONECTIN; FOCAL ADHESION KINASE 1; GELATINASE A; GELATINASE B; JANUS KINASE 1; JANUS KINASE 2; LAMIN B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; RY 10 4; TUBULIN; UNCLASSIFIED DRUG; UVOMORULIN; 2-(1-HYDROXY-4-OXOCYCLOHEXA-2,5-DIENYL)PYRAN-4-ONE; CADHERIN; PYRONE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; TUMOR INVASION; UPREGULATION; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PATHOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; BLOTTING, WESTERN; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PYRONES;

EID: 84901611403     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.03.003     Document Type: Article

References (30)

1. Susumu S., Hiromi J., Kenichi W., Masato T. Does primary tumor resection improve outcomes for patients with incurable advanced breast cancer. Breast 2011, 20:543-547.
2. Yilmaz M., Christofori G., Lehembre F. Distinct mechanisms of tumor invasion and metastasis. Trends Mol Med 2007, 13(12):535-541.
3. Nguyen D.X., Bos P.D., Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009, 9:274-284.
4. Chen J.Q., Russo J. ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 2009, 1796:162-175.
5. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metast Rev 2006, 25:29-34.
6. St-Pierre Y., Van Themsche C., Esteve P.O. Emerging features in the regulation of MMP-9 gene expression for the development of novel molecular targets and therapeutic strategies. Curr Drug Targets 2003, 2:206-215.
7. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
8. Birchmeier W., Behrens J. Cadherin expression in carcinomas: Role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta 1994, 1198:11-26.
9. Jiang W.G., Robert E. Mansel E-cadherin complex and its abnormalities in human breast cancer. Surg Oncol 2000, 9:151-171.
10. Blaschuk O.W., Devemy E. Cadherins as novel targets for anti-cancer therapy. Eur J Pharmacol 2009, 625:195-198.
11. Chen H.J., Hsu L.S., Shia Y.T., Lin M.W., The Lin C.M. β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway. Biochem Phamacol 2012, 84:1143-1153.
12. Fu D.Y., Wang Z.M., Shao Z.M. Sox17, the canonical Wnt antagonist, is epigenetically inactivated by promoter methylation in human breast cancer. Breast Cancer Res Treat 2010, 119:601-612.
13. Berry J.M., Bradshaw T.D., Westwell A.D., et al. Quinols as Novel Therapeutic Agents. 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and RelatedAgents as Potent and Selective Antitumor Agents. J Med Chem 2005, 48:639-644.
14. Yuan Q.Y., Cai S.X., Zhang X.N., Liu Z.W., Ruan J.L., et al. A new protoapigenone analog RY10-4 induces apoptosis and suppresses invasion through the PI3K/Akt pathway in human breast cancer. Cancer Lett 2012, 324:210-220.
15. Virtanen S.S., Vaananen H.K., Harkonen P.L., Lakkakorpi P.T. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting themevalonate pathway. Cancer Res 2002, 62:2708-2714.
16. Giuseppina C., Maura C., Paola C., et al. HIF-1α stabilization by mitochondrial ROS promotes Met-dependent invasive growth and vasculogenic mimicry in melanoma cells. Free Radic Biol Med 2011, 51:893-894.
17. Hart I.R., Saini A. Biology of tumour metastasis. Lancet 1992, 339:1453-1457.
18. Ahn G.O., Brown J.M. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: Role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008, 13:193-195.
19. Laezza C., D'Alessandro A., Bifulco M. Anandamide inhibits the Wnt/β-catenin signalling pathway in human breast cancer MDA-MB-231 cells. Eur J Cancer 2012, 48:3112-3122.
20. Jamieson C., Sharma M., Beric R. Henderson Wnt signaling from membrane to nucleus: β-catenin caught in a loop. Int J Biochem Cell Biol 2012, 44:847-850.
21. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
22. Rodriguez F.J., Lewis-Tuffin L.J., Anastasiadis P.Z. E-cadherin's dark side: Possible role in tumor progression. Biochim Biophys Acta 2012, 1826:23-31.
23. Del Muro X.G., Torregrosa A., Munoz J. Germa JR Prognostic value of the expression of E-cadherin and β-catenin in bladder cancer. Eur J Cancer 2000, 36:357-362.
24. Serafino A., Moroni N., Pierimarchi P. Anti-proliferative effect of atrial natriuretic peptide on colorectal cancer cells: Evidence for an Akt-mediated cross-talk between NHE-1 activity and Wnt/β-catenin signaling. Biochim Biophys Acta 2012, 1822:1004-1018.
25. Gong Y.D., Dong M.S., Kang N.S. A novel 3-arylethynyl-substituted pyrido[2,3,-b]pyrazine derivatives and pharmacophore model as Wnt2/β-catenin pathway inhibitors in non-small-cell lung cancer cell lines. Bioorg Med Chem 2011, 19:5639-5647.
26. Lee K.H., Hyun M.S., Kim J.R. Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. Clin Exp Metastasis 2003, 20:499-505.
27. Wang X.Y., Wang Y., Liu H.C. Tamoxifen lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of ER-positive non-small cell lung cancer cells. Biomed Pharmacother 2011, 65(7):525-528.
28. Wang Y., Botvinick E.L., Zhao Y., Berns M.W., Usami S., et al. Visualizing the mechanical activation of Src. Nature 2005, 434:1040-1045.
29. Webb D.J., Donais K., Whitmore L.A., Thomas S.M., Turner C.E., et al. FAK-Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly. Nat Cell Biol 2004, 6:154-161.
30. Mitra S.K., Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006, 18:516-523.